Modifying soft tissue sarcoma chemotherapy regimens. Old drugs and new horizons
Abstract
We report results of single institution trial of 78 STS pts treated with front line high dose doxorubicin with ifosfamide in comparison with 50 pts treated retrospectively with standard MAID regimen. We achieved 44% increase in PFS (from 5 to 7.2 month) and OS (from 10 to 19.2 month) in high dose subgroup (p=0.00001). New regimen showed high activity and durable toxicity profile and can be used routinely only in specialized sarcoma centers across the country.
About the Author
A. A. Fedenko
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
References
1. Patel S.R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R.S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378.
2. Billingsley K.G., Burt M.E., Jara E., Ginsberg R.J., Woodruff J.M., Leung D.H., Brennan M.F. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann. Surg. 1999, v. 229 (5), p. 602.
3. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing firstline regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 1999, v. 17 (1), p. 150.
4. Benjamin R.S., WiernikP.H., Bachur N.R. Adriamycin: a new effective agent in the therapy of disseminated sarcomas Med. Pediatr. Oncol. 1975, v. 1 (1), p. 63.
5. Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., Lerner H.J., Carbone P.P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 1987, v. 5 (6), p. 840.
6. Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., Lerner H.J., Carbone P.P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. Clin. Oncol. 1987, v. 5 (6), p. 840.
7. Judson I., Radford J.A., Harris M., Blay J.Y., van Hoesel Q., le Cesne A., van Oosterom A.T., Clemons M.J., Kamby C., Hermans C., Whittaker J., Donato di Paola E., Verweij J., Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2001, v. 37 (7), p. 870.
8. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 1995, v. 13 (7), p. 1537.
9. Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S., Shiraki M., Frytak S., Parkinson D.R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 1993, v. 11 (7), p. 1269.
10. Borden E.C., Amato D.A., Edmonson J.H., Ritch P.S., Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 1990, v. 66 (5), p. 862.
11. Houridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, v. 23 (10), p. 1477.
12. Schoenfeld D.A., Rosenbaum C., Horton J., Wolter J.M., Falkson G., De Conti R.C. Acomparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982, v. 50 (12), p. 2757.
13. Demetri G.D., Elias A.D. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol. Oncol. Clin. North Am. 1995, v. 9 (4), p. 765.
14. Nielsen O.S., Dombernowsky P., Mouridsen H., Crowther D., Verweij J., Buesa J., StewardW., Daugaard S., van GlabbekeM., KirkpatrickA., TurszT. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer. 1998, v. 78 (12), p. 1634.
15. Mouridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, v. 23 (10), p. 1477.
16. Patel S.R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R.S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378.
17. Van Oosterom A.T., Mouridsen H.T., Nielsen O.S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., van GlabbekeM., Verweij J. EORTC Soft Tissue and Bone Sarcoma Group Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer. 2002, v. 38 (18), p. 2397.
18. Antman K.H., Ryan L., Elias A., Sherman D., Grier H.E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J. Clin. Oncol. 1989, v. 7 (1), p. 126.
19. Nielsen O.S., Judson I., van Hoesel Q., le Cesne A., Keizer H.J., Blay J.Y., van Oosterom A., Radford J.A., Svancárová L., Krzemienlecki K., Hermans C., van Glabbeke M., Oosterhuis J.W., Verweij J. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2000, v. 36 (1), p. 61.
20. Cerny T., Leyvraz S., von Briel T., Küpfer A., Schaad R., Schmitz S.F., Honegger P., Sessa C., Brunner J., Boddy A.V. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 1999, v. 10 (9), p. 1087.
21. Buesa J.M., López-Pousa A., Martín J., Antón A., García del Muro J., Bellmunt J., Arranz F., Valentí V., Escudero P., Menéndez D., Casado A., Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann. Oncol. 1998, v. 9 (8), p. 871.
22. Van Oosterom A.T., Mouridsen H.T., Nielsen O.S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., van GlabbekeM., Verweij J. EORTC Soft Tissue and Bone Sarcoma Group Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer. 2002, v. 38 (18), p. 2397.
23. Palumbo R., Palmeri S., Antimi M., Gatti C., Raffo P., Villani G., Toma S. Phase II study of continuous-infusion highdose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann. Oncol. 1997, v. 8 (11), p. 1159.
24. Le Cesne A., Antoine E., Spielmann M., Le Chevalier T., Brain E., Toussaint C., Janin N., Kayitalire L., Fontaine F., Genin J. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 1995, v. 13 (7), p. 1600.
25. Rahal A.S. et al. High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. J. Clin. Oncol. 30, 2012 (suppl; abstr. 10044).
26. Lorigan P., Verweij J., Papai Z., Rodenhuis S., Le Cesne A., Leahy M.G., Radford J.A., van Glabbeke M.M., Kirkpatrick A., Hogendoorn P.C., Blay J.Y. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 2007, v. 25 (21), p. 3144.
27. Bramwell V.H., Mouridsen H.T., Santoro A., Blackledge G., Somers R., Verweij J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 1993, v. 31, Suppl. 2, p. 180.
28. Judson I., Verweij J., Gelderblom H., Hartmann J.T., Schöffski P., Blay J.Y., Kerst J.M., Sufliarsky J., Whelan J., Hohenberger P., Krarup-Hansen A., Alcindor T., Marreaud S., Litière S., Hermans C., Fisher C., Hogendoorn P.C., Dei Tos A.P., van der Graaf W.T. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014, v. 15 (4), p. 415.
29. Bramwell V.H., Anderson D., CharetteM.L. Sarcoma Disease Site Group Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst. Rev. 2003.
30. Blay J.Y., van Glabbeke M., Verweij J., van Oosterom A.T., Le Cesne A., Oosterhuis J.W., Judson I., Nielsen O.S. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. ur J. Cancer. 2003, v. 39 (1), p. 64.
Review
For citations:
Fedenko A.A. Modifying soft tissue sarcoma chemotherapy regimens. Old drugs and new horizons. Bone and soft tissue sarcomas, tumors of the skin. 2015;(4):3-19. (In Russ.)
Views:
179
Email this article 
